Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Monopar Therapeutics Inc (MNPR)
NASDAQ:MNPR
RESEARCH TOOLSreports
Holding MNPR?
Track your performance easily
MNPR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.37 - $8.65
Previous Close$4.16
Volume98.09K
Average Volume (3M)742.45K
Market Cap
$14.64M
Enterprise Value$8.52M
Total Cash (Recent Filing)$6.12M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Mar 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.30
Shares Outstanding3,520,365
10 Day Avg. Volume4,253,167
30 Day Avg. Volume742,451
Standard Deviation0.28
R-Squared0.05
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)2.40
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.91
Forecast
1Y Price Target
$7.50Price Target Upside90.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Monopar Therapeutics Inc News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMNPR recently announced the clearance to start a Phase I therapeutic trial of MNPR-101-Lu in Australia.
Financial PerformanceAnalysts maintain a Buy rating of MNPR and increase the 12-month price target to $6.00 per share, up from $2.00.
Preclinical DataThe preclinical results demonstrate the tumor-targeting ability of MNPR-101 and near complete elimination of tumors in xenograft mouse models after a single injection.
Bears Say
Capital And CompetitionFailure to secure capital raise and competitive pressure pose significant risks.
Clinical TrialsKey risks include clinical trial failure and safety concerns with camsirubicin at high dose levels.
Financial PerformanceThe company reported no revenues and a net loss of $0.10 per share.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MNPR FAQ
What was Monopar Therapeutics Inc’s price range in the past 12 months?
Monopar Therapeutics Inc lowest stock price was $1.36 and its highest was $8.64 in the past 12 months.
What is Monopar Therapeutics Inc’s market cap?
Currently, no data Available
When is Monopar Therapeutics Inc’s upcoming earnings report date?
Monopar Therapeutics Inc’s upcoming earnings report date is Mar 20, 2025 which is in 182 days.
How were Monopar Therapeutics Inc’s earnings last quarter?
Monopar Therapeutics Inc released its earnings results on Aug 09, 2024. The company reported -$0.5 earnings per share for the quarter, the consensus estimate of -$0.5 by $0.
Is Monopar Therapeutics Inc overvalued?
According to Wall Street analysts Monopar Therapeutics Inc’s price is currently Undervalued.
Does Monopar Therapeutics Inc pay dividends?
Monopar Therapeutics Inc does not currently pay dividends.
What is Monopar Therapeutics Inc’s EPS estimate?
Monopar Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Monopar Therapeutics Inc have?
Monopar Therapeutics Inc has 3,520,365 shares outstanding.
What happened to Monopar Therapeutics Inc’s price movement after its last earnings report?
Monopar Therapeutics Inc reported an EPS of -$0.5 in its last earnings report, expectations of -$0.5. Following the earnings report the stock price went down -19.636%.
Which hedge fund is a major shareholder of Monopar Therapeutics Inc?
Currently, no hedge funds are holding shares in MNPR
---
Monopar Therapeutics Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.50 (90.36% Upside)
$7.50 (90.36% Upside)
Insider Transactions
Bought Shares
Worth $25.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 12.3%
Last 30 Days ▲ 8.8%
Last 30 Days ▲ 8.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
37.42%
12-Months-Change
Fundamentals
Return on Equity
-102.31%
Trailing 12-Months
Asset Growth
-30.55%
Trailing 12-Months
Company Description
Monopar Therapeutics Inc
Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
---
MNPR Stock 12 Month Forecast
Average Price Target
$7.50
▲(90.36% Upside)
Technical Analysis
Best Analysts Covering MNPR
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
-16.05%
reiterated a buy rating last month
Copying Sean Lee CFA's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -16.05% per trade.
---